World Health Organization

WHO COVID-19 vaccines research

Emerging evidence on additional doses of COVID-19 vaccines and their safety

Salle A - 25 October 2021

13:00 – 19:10 Central European Time CET

Agenda

R&DBlueprint

Powering research
to prevent epidemics

OBJECTIVES OF THE MEETING

In continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a follow-up consultation on emerging evidence on safety and the need for additional doses of COVID-19 vaccines.

The objectives of this forthcoming consultation will be to review the available evidence on vaccines being deployed in terms of:

- Safety in naïve and previously vaccinated populations
- Updated evidence and considerations regarding the administration of additional doses

Chairperson: Philip Krause

Time	Topic	Speakers
13:00 - 13:10	Global overview of the epidemiologic situation	Maria van Kerkhove
13:10 - 13:20	Objectives of the meeting	Philip Krause
13:20 - 13:30	Current recommendations from SAGE regarding COVID-19 vaccines	Hanna Nohynek
Session 1. What do we know and what additional evidence is needed to inform decisions on safety in naïve and previously vaccinated populations?		
13:30 - 13:40	COVID-19 Myocarditis	Dan Sado
13:40 - 14:10	Experience with COVID-19 vaccines and myocarditis in selected countries	Tom Shimabukuro – VSD (USA) Hui-Lee Wong - FDA (USA) – mRNA vaccines Narayan Nair – FDA (USA) – Non replicating viral vector
14:10 - 14:30	What conclusions can be drawn from the totality of the evidence?	Panel Discussion moderated by **Terry Nolan** Participants from above talks
14:30 - 15:00	Evidence of vaccine safety, developer's perspective	CanSinoBIO - Xuefeng Yu Janssen - Macaya Douoguih Medigen - Allen Lien Moderna - Randy Hyer Sinopharm - Li Meng Sinovac - Liming Wang (All developers with vaccines deployed were invited)
15:00 - 15:45	Lessons learned from monitoring vaccine safety	Panel Discussion moderated by **Rogerio Gaspar** Speakers invited from regulatory authorities Gustavo Santos & Brenda Valente, ANVISA (Brazil) Marco Cavaleri, EMA (Europe) Seth Seaneke, Ghana FDA Michael Rosu-Myles & Dean Smith, Health Canada Marie-Christine Bielsky MHRA (UK) Svein Rune Andersen, Norwegian Medicines Agency Portia Nkambule, SAHPRA (South Africa) Peter Marks, US FDA (USA)

15:45 - 16:05	What additional research and strategies are needed?	Panel Discussion moderated by **Helen Rees** Rita Helfand Mary Ramsay Susan Ellenberg Hanna Nohynek Benjamin Ong
16:05 – 16:10	**BREAK**	
Session 2. Updated evidence and considerations regarding the administration of additional doses		
16:10 – 16:30	Emerging data from Israel	Sharon Alroy-Preis Ron Milo
16:30 - 16:40	COVID-19 vaccine effectiveness by product and timing in New York state	Eli Rosenberg
16:40 - 17:10	Emerging data from Brazil	Daniel Villela Manoel Barral Netto Rosana Leite de Melo
17:10 – 17:20	Emerging data from Chile	Rafael Araos
17:20 - 17:35	Observational evidence on vaccine effectiveness against the delta variant – latest results and risk of bias considerations	Julian Higgins
17:35 – 18:05	Emerging data on homologous and heterologous boosting	Reinhold Förster Rory de Vries Matthew Snape Robert Atmar
18:05 - 18:50	Booster Doses: Overview of evidence and remaining gaps	Panel Discussion moderated by **Liz Miller** Peter Figueroa Narendra Arora Ricardo Ruttimann Lelièvre Jean-Daniel Sharon Alroy-Preis Ron Milo Manoel Barral Netto Rosana Leite de Melo Rafael Araos Eli Rosenberg Dan Barouch
18:50 - 19:10	Synthesis of the Evidence and Next Steps	Philip Krause
19:10	**END OF MEETING**	